Crenessity

Active Ingredient(s): Crinecerfont
FDA Approved: * December 13, 2024
Pharm Company: * NEUROCRINE
Category: Genetic Disorders
* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Crenessity 25 mg Oral Capsule
NDC: 70370-5025
Labeler:
Neurocrine Biosciences, Inc.
Crenessity 50 mg Oral Capsule
NDC: 70370-5050
Labeler:
Neurocrine Biosciences, Inc.
Crenessity 100 mg Oral Capsule
NDC: 70370-5100
Labeler:
Neurocrine Biosciences, Inc.
Crenessity 50 mg/ml Oral Solution
NDC: 70370-5250
Labeler:
Neurocrine Biosciences, Inc.